Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis
NCT04053374 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 275
Last updated 2020-04-24
Summary
The aim of this research is to understand how lipids such as cholesterol affect the disease process in people with MS.
Conditions
Interventions
- OTHER
-
Blood sampling
Blood sampling +/- CSF sampling
Sponsors & Collaborators
-
University College London Hospitals
collaborator OTHER -
University College, London
lead OTHER
Principal Investigators
-
Rachel Farrell, Dr · UCL & University College London Hospitals NHS Foundation Trust
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-09-01
- Primary Completion
- 2020-06-30
- Completion
- 2020-06-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
NCT05072691 ·Status: RECRUITING
-
Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic
NCT05056740 ·Status: RECRUITING
-
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
NCT04201470 ·Status: COMPLETED ·Phase: NA
-
Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases
NCT05088473 ·Status: COMPLETED
-
Functional Outcomes From Diets in Multiple Sclerosis
NCT05327322 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Testing Mitochondria Activity and Blood Lipid Content of Multiple Sclerosis Patients
NCT01918501 ·Status: UNKNOWN ·Phase: NA
-
A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis
NCT01538355 ·Status: COMPLETED ·Phase: NA
-
Low Fat Diet and Multiple Sclerosis
NCT00852722 ·Status: COMPLETED ·Phase: PHASE1
-
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT04873492 ·Status: RECRUITING ·Phase: NA
-
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
NCT02133664 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Nutritional Approaches in Multiple Sclerosis
NCT03508414 ·Status: UNKNOWN ·Phase: NA
-
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
NCT04380220 ·Status: UNKNOWN
-
Study on Cognitive Disorders of Multiple Sclerosis
NCT01074619 ·Status: COMPLETED ·Phase: PHASE3
-
Time Restricted Eating Outcomes in Multiple Sclerosis
NCT04389970 ·Status: COMPLETED ·Phase: NA
-
Behavioural Activation for Low Mood in Multiple Sclerosis
NCT03935529 ·Status: COMPLETED ·Phase: NA
-
Study of Empathy in MS
NCT05332951 ·Status: COMPLETED
-
Retrospective Study on the Role of SCFA Modulation in Multiple Sclerosis
NCT06746896 ·Status: ACTIVE_NOT_RECRUITING
-
COVID-19 and Multiple Sclerosis Disease Modifying Therapies
NCT04863586 ·Status: UNKNOWN
-
Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients
NCT02789670 ·Status: COMPLETED
-
Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis
NCT05033782 ·Status: COMPLETED
-
Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis
NCT03302442 ·Status: COMPLETED
-
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
NCT04798651 ·Status: RECRUITING ·Phase: NA
-
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
NCT01395316 ·Status: COMPLETED ·Phase: PHASE4
-
Multiple Sclerosis and the Effects of Ketogenic Diet Therapy
NCT06715436 ·Status: RECRUITING ·Phase: NA
-
Intrathecal Rituximab in Progressive Multiple Sclerosis
NCT02545959 ·Status: COMPLETED ·Phase: PHASE2